Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
10/2005
10/25/2005US6958159 Pharmaceutical gel composition
10/25/2005CA2359708C Ketolide antibiotics
10/25/2005CA2332461C New benzenesulfonamide derivatives, their method of preparation and the pharmaceutical compositions containing them
10/25/2005CA2147056C Novel delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides
10/25/2005CA2110454C 1,5,7-trisubstituted indoline compounds for the treatment of dysuria
10/25/2005CA2084301C Heparin derivatives and process for the preparation thereof
10/21/2005CA2504582A1 Drug delivery device comprising a bilayered polymeric coating having an inhibitor of the mamalian target of rapamycin incorporated into the first polymeric coating layer
10/21/2005CA2504401A1 Drug delivery systems for the prevention of neointimal hyperlasia
10/20/2005WO2005097814A2 Composition and method for inhibiting platelet aggregation
10/20/2005WO2005097782A1 Piperidine derivative
10/20/2005WO2005097738A1 Novel sulfonamide derivative
10/20/2005WO2005097194A1 Sustained release formulation for oral administration of hmg-coa reductase inhibitor and method for the preparation thereof
10/20/2005WO2005097177A1 Use of collagenase to facilitate guide wire crossing in total arterial occlusions
10/20/2005WO2005097170A1 Angiogenesis promoter and angiogenic therapy
10/20/2005WO2005097152A1 Turmeric extract-containing composition having improved caking capacity
10/20/2005WO2005097151A1 Antioxidant composition and products containing the same
10/20/2005WO2005097145A1 Myocarditis treatment
10/20/2005WO2005097118A1 Aldosterone receptor antagonists
10/20/2005US20050235367 Regulatory sequences capable of conferring expression of a heterologous DNA sequence in endothelial cells and uses thereof
10/20/2005US20050234248 Method of producing preparations rich in tocotrienol
10/20/2005US20050234245 Estrogen receptor modulators
10/20/2005US20050234133 Use of fingolimod or salt
10/20/2005US20050234130 Medicament for therapeutic treatment of vascular disease
10/20/2005US20050234129 Salts of nateglinide
10/20/2005US20050234126 Amide derivatives as inhibitors of the enzymatic activity of renin
10/20/2005US20050234118 Novel aryllimidazole derivatives, preparation and therapeutic used thereof
10/20/2005US20050234116 e.g. 4-(4-chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-(2-methylphenoxy)propyl]oxazole; voltage-dependent anion channel, mitochondria porin modulator, apoptosis suppressor, mitochondria function ameliorator; Down syndrome, pigmentary degeneration of retina, alcoholic hepatitis or sideroblastic anemia
10/20/2005US20050234105 Method of treating of demyelinating diseases or conditions
10/20/2005US20050234096 Tetrahydroisoquinoline derivatives
10/20/2005US20050234090 Modulators of chemokine receptor activity
10/20/2005US20050234089 Anti-infective agents and/or immunomodulators used for preventive therapy following an acute cerebrovascular accident
10/20/2005US20050234083 Diamino-pyrimidines and their use as angiogenesis inhibitors
10/20/2005US20050234081 for inhibiting the enzyme C1s, a protease in the classical pathway of the complement system; and the use of this inhibition to treat or ameliorate acute or chronic disorders in mammals
10/20/2005US20050234079 Novel crystalline form of 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl]methoxy] benzyl]thiazolidine-2,4-dione potassium salt
10/20/2005US20050234077 Pyrimidine compounds and their use as modulators of chemokine receptor activity
10/20/2005US20050234062 Such as 2-{4-[(4aS,8aR)-4-(3,4-dimethoxyphenyl)-1-oxo-4a,5,8,8a-tetrahydro-1H-phthalazin-2-yl]-piperidin-1-yl}-2H-acetamide; phosphodiesterase inhibitors; for treatment of respiratory disorders
10/20/2005US20050234061 N-[3-(4-chlorophenyl)-2-(3-pyridyl)-1-methylpropyl]-2-(5-trifluoromethyl-2-pyridyloxy)-2-methylpropanamide; obesity; antipsychotic agents; synergistic; cannabinoid receptor antagonists
10/20/2005US20050234056 Imidazoquinoline derivatives as adenosine A3 receptor ligands
10/20/2005US20050234051 5-Substituted 2-aryl-4 pyrimidinones
10/20/2005US20050234048 substituted 4,5-dihydro-1H-benzo[b][1,4]-diazepin-2-one; amidation of a substituted monoprotected 1,2-diaminobenzene with an ester, deprotecting, cyclization; chronic neurological disorders, psychosis, schizophrenia, Alzheimer's disease
10/20/2005US20050234041 Substituted 1-benzazepines and derivatives thereof
10/20/2005US20050234035 New salts
10/20/2005US20050234029 Compounds
10/20/2005US20050234028 solid dosage form for contraceptives and hormone replacement therapy; very low moisture content to prevent ester hydrolysis; enhanced bioavailability of 17-beta-estradiol
10/20/2005US20050234022 Use of 2-alkoxyphenyl-substituted imidazotriazinones
10/20/2005US20050234017 Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
10/20/2005US20050234015 Low molecular weight heparin salt with triethanolamine useful as therapeutic-antitrombotic agent of local delivery, procedures for preparing them, process for elimination of hygroscopicity of heparin salt, pharmaceutical compositions for local use in antithrombotic therapy and uses therein
10/20/2005US20050234008 Diagnosis of a person's risk of developing atherosclerosis or diabetic retinopathy based on leucine 7 to proline 7 polymorphism in the prepro-neuropeptide Y gene
10/20/2005US20050233992 Regeneration of endogeneous myocardial tissue by induction of neovascularization
10/20/2005US20050233969 Analogues of GLP-1
10/20/2005US20050233956 Proteins involved in the regulation of energy homeostasis
10/20/2005US20050233452 Cell populations which co-express CD49c and CD90
10/20/2005US20050233447 A cell simultaneously expressing albumin protein and a membrane-associated CD14 surface antigen; expresses a mRNA sequence typical of hepatocytes selected from the group consisting of alpha-fetoprotein, carbamyl phosphate synthetase I, coagulation factor II, and coagulation factor VII
10/20/2005US20050233402 Heparinase III HLGAG fragments and uses thereof
10/20/2005US20050233361 PPARdelta assay
10/20/2005US20050233359 Isolated nucleic acid molecule encoding a neurotrophic growth factor
10/20/2005US20050233328 Methods of identifying compounds that modulate protein activity
10/20/2005US20050233326 Drug screening for binding property or signal transduction between a G protein-coupled receptor and humanin or a salt; Alzheimer*s disease
10/20/2005US20050232965 Local administration of a combination of rapamycin and 17 beta-estradiol for the treatment of vulnerable plaque
10/20/2005US20050232916 Novel screens to identify agents that modulate retinal blood vessel function and pericyte function and diagnostic and therapeutic application therefor
10/20/2005US20050232908 Novel use of the extract of processed ginseng and saponin isolated therefrom
10/20/2005US20050232870 Method of treatment of dopamine-related dysfunction
10/20/2005US20050232860 Use of edg-receptor agonists for the treatment of hypertension
10/20/2005CA2565324A1 Method of reducing c-reactive protein using growth hormone secretagogues
10/20/2005CA2561958A1 Composition and method for inhibiting platelet aggregation
10/20/2005CA2561951A1 Extracts of passion fruit and uses thereof
10/20/2005CA2561645A1 A method of treatment for stroke employing administration of defibrinogenating agents to achieve a specific defibrinogenation pattern
10/20/2005CA2561280A1 Substituted pyridones as inhibitors of poly(adp-ribose) polymerase (parp)
10/20/2005CA2557850A1 Methods of treatment using eszopiclone
10/20/2005CA2557010A1 Compounds and methods for treating dyslipidemia
10/19/2005EP1586644A2 Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour development and for wound healing
10/19/2005EP1586635A1 Fusion proteins with parts of immunoglobulins, their production and use
10/19/2005EP1586586A2 Peptide and/or proteins and their use for the manufacture of a therapeutic and/or preventive medicament
10/19/2005EP1586567A1 Compounds useful in the treatment of inflammatory diseases
10/19/2005EP1586564A1 8-azaprostaglandin derivatives and medicinal uses thereof
10/19/2005EP1586349A1 Controlled release of anti-arrhythmic agents
10/19/2005EP1586347A1 Electrically assisted lidocaine and epinephrine delivery device having extended shelf-stability
10/19/2005EP1586337A2 The local administration of a combination of rapamycin and 17 beta-estradiol for the treatment of vulnerable plaque
10/19/2005EP1586328A1 Agent for improving life expectancy in therapy of malignant tumor
10/19/2005EP1586326A1 Pharmaceutical compositions for treating neuronal damage and neurodegenerative diseases
10/19/2005EP1586322A2 Compositions for inhibition of anglogenesis
10/19/2005EP1585959A2 Extended glucagon-like peptide-1 analogs
10/19/2005EP1585762A1 Means for regulating the expression of human isoforms of ant
10/19/2005EP1585733A1 Heterocyclic ppar modulators
10/19/2005EP1585730A1 Carboxamide derivatives and their use as factor xa inhibitors
10/19/2005EP1585522A2 Quinazolinones as potassium channel modulators
10/19/2005EP1585508A2 Use of sphingolipids for reducing plasma cholesterol and triacylglycerol levels
10/19/2005EP1487272B1 Choline-silicic acid complex with osmolytes and divalent trace elements
10/19/2005EP1463714A4 Vanilloid receptor ligands and their use in treatments
10/19/2005EP1432683B1 Novel crystalline polymorphic forms of lercanidipine hydrochloride and processes for their preparation
10/19/2005EP1423117B1 2-substituted 1-arylpiperazines as tachykinin antagonists and/or serotonin reuptake inhibitors
10/19/2005EP1414837B1 Adenosine a3 receptor agonists
10/19/2005EP1401837B1 Purine derivatives as a2b adenosine receptor antagonists
10/19/2005EP1397170B1 Safety shield system for prefilled syringes
10/19/2005EP1370554B1 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors
10/19/2005EP1345616A4 Reducing cellular damage in the human body
10/19/2005EP1337523B1 2,4-substituted pyridine derivatives
10/19/2005EP1311263B1 Fused pyrrolocarbazoles against inflammation
10/19/2005EP1307245B1 Pharmaceutical form comprising a cell regulating factor and/or a cell proliferation promoter
10/19/2005EP1255740B1 Substituted arylpyrazines
1 ... 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 ... 1595